Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared a post by NEJM on X, adding:
“Great work coming out today evaluating a reactivatior (Rezatopopt) in TP53-Y220C mut solid cancers.
We are running a trial with rezatopopt in TP53-Y220C mutated MDS/AML: actively recruiting and can potentially benefit such patients.”
Quoting NEJM’s post:
“In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%.
Full PYNNACLE study results.”
Title: Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors
Authors: Ecaterina Dumbrava, Geoffrey Shapiro, Aparna Parikh, Melissa Johnson, Anthony Tolcher, John Thompson, Anthony El-Khoueiry, Andrae Vandross, Shivaani Kummar, Dale Shepard, Kim LeDuke, Lisa Sheehan, Leila Alland, Arshad Haque, Deepika Jalota, Marc Fellous, Alison Schram
Read the Full Article.
“Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors.”
Title: Restoring Function to a Variant of p53 in Solid Tumors
Author: Xin Lu
Read the Full Article.
Other articles featuring Jayastu Senapati.
